• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Video: Toward Safe Use of Opioids

Article
Conference|ACP

Once you've decided that an opioid analgesic is indicated, what can you do to ensure that your patient uses the medication safely?

Once you’ve decided that an opioid analgesic is indicated, what can you do to ensure that your patient uses the medication safely?

Here, Leanne M. Yanni, MD, addresses that question and offers some practical advice. Dr Yanni is Assistant Professor in the Department of Internal Medicine and Palliative Care at Virginia Commonwealth University Medical Center in Richmond.

Related Content
Racial Minorities Less Likely to Receive CPR Regardless of Location, Community Makeup

Racial Minorities Less Likely to Receive CPR Regardless of Location, Community Makeup

April 1st 2022
Article

ACC 2022. Black and Hispanic persons were 41% less likely than white individuals to receive CPR after cardiac arrest in public and 26% less likely when the event occurred in their home.

Depression Following Myocardial Infarction Raises Stroke Risk in US Adults

Depression Following Myocardial Infarction Raises Stroke Risk in US Adults

March 30th 2022
Article

ACC 2022. Large study of US adults showed those with depression following MI were 50% more likely to experience a stroke than those who did not have depression.

Mepolizumab Clinically Effective Regardless of Type 2 Biomarker Status in Patients with Severe Asthma, Suggests Real-world Data

Mepolizumab Clinically Effective Regardless of Type 2 Biomarker Status in Patients with Severe Asthma, Suggests Real-world Data

February 28th 2022
Article

AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.

Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis

Dupilumab Found to Improve Clinical, Histologic Aspects of Eosinophilic Esophagitis

February 26th 2022
Article

AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.

chronic hives, chronic Spontaneous Urticaria

Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria

February 26th 2022
Article

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Tezepelumab Found Effective in Reducing Exacerbations in Moderate-to-Severe, Uncontrolled Asthma

Tezepelumab Found Effective in Reducing Exacerbations in Moderate-to-Severe, Uncontrolled Asthma

February 11th 2022
Article

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

© 2024 MJH Life Sciences

All rights reserved.